닥플 플러스
KSMO 2026(2일차)
대한종양내과학회(17.5 명칭변경 한국임상암학회)
연수평점 :6점
오프라인
주관
대한종양내과학회(17.5 명칭변경 한국임상암학회)
교육일자
2026-09-03
수강료
300,000원
교육형태
오프라인
등록일시
2026-08-07
교육시간
34시간 30분
연수평점
6점
장소
서울특별시 그랜드 인터컨티넨탈 서울 파르나스 그랜드볼룸 A,B, 오키드룸, 매그놀리아룸, 로즈룸
교육종류
내과
타임테이블
| 날짜 | 시간 | 강의명 | 강사 | 구분 |
|---|---|---|---|---|
| 2026-09-03 | 08:30~08:52 | The frontier of neoadjuvant therapy for breast cancer | Elizabeth Mittendorf(Dana-Farber Cancer Institute, USA) | - |
| 2026-09-03 | 08:52~09:14 | Therapy de-escalation in the era of neoadjvuant therapy for resectable melanoma | Michael Lowe(Winship Cancer Institute, Emory University, USA) | - |
| 2026-09-03 | 09:14~09:36 | Recent advances in perioperative strategies in Gastric/GEJ cancer | Byung Woog Kang(Kyungpook National University Chilgok Hospital, Korea) | - |
| 2026-09-03 | 09:36~10:00 | Neoadjuvant and perioperative strategies in breast cancer | Sung-Bae Kim(Asan Medical Center, Korea) | - |
| 2026-09-03 | 10:00~10:10 | 휴식 | - | - |
| 2026-09-03 | 10:10~10:30 | Opening Ceremony | - | - |
| 2026-09-03 | 10:30~11:10 | New concepts in cancer biology: From the microbiome to non-coding DNA | Emile E. Voest(Netherlands Cancer Institute and Oncode Institute, Netherlands) | - |
| 2026-09-03 | 11:10~11:20 | 휴식 | - | - |
| 2026-09-03 | 11:20~12:00 | Beyond the changes: Mastering strategic regimens in 2026 gastric cancer | Sung-Hee Lim(Samsung Medical Center, Korea) | - |
| 2026-09-03 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-03 | 12:10~12:35 | Expanding the curative horizon through neoadjuvant chemo-immunotherapy in gastric cancer | Sun Young Rha(Yonsei Cancer Center, Korea) | - |
| 2026-09-03 | 12:35~13:00 | Optimizing strategies for future surgical resection of localized PDAC | Jung Yong Hong(Samsung Medical Center, Korea) | - |
| 2026-09-03 | 13:00~13:30 | Synergizing locoregional and systemic therapy for HCC: A multimodal path to cure | Peng Wang(Zhongshan hospital, China) | - |
| 2026-09-03 | 13:30~13:50 | 휴식 | - | - |
| 2026-09-03 | 13:50~14:12 | AI models for precision medicine | Mihaela Aldea(Gustave Roussy, Villejuif, France) | - |
| 2026-09-03 | 14:12~14:34 | How to use generative AI in daily practice | Fabrice André(Gustave Roussy, Villejuif, France) | - |
| 2026-09-03 | 14:34~14:56 | Data for AI in oncology: A synthetic data integration approach | Hyunwook Kim(Yonsei Cancer Center, Korea) | - |
| 2026-09-03 | 14:56~15:20 | Prediction of immunotherapy related AE using AI | Sook Ryun Park(Asan Medical Center, Korea) | - |
| 2026-09-03 | 15:20~15:30 | 휴식 | - | - |
| 2026-09-03 | 15:30~16:10 | Targeting RAS: What have we learned? What are we learning? What do we need to learn? | David S. Hong(MD Anderson Cancer Center, USA) | - |
| 2026-09-03 | 16:10~16:32 | Redefining HER2 and beyond: Biomarker-driven use of ADCs | Elaine Lim Hsuen(National Cancer Center Singapore, Singapore) | - |
| 2026-09-03 | 16:32~16:54 | ctDNA and liquid biopsy in breast cancer: Clinical decision-making across disease continuum | Jieun Lee(The Catholic University of Korea Seoul St. Mary’s Hospital, Korea) | - |
| 2026-09-03 | 16:54~17:16 | Homologous recombination deficiency beyond BRCA: Biology, biomarkers and therapeutic opportunities | Ji Hyung Hong(National Cancer Center, Korea) | - |
| 2026-09-03 | 17:16~17:40 | Biomarkers for immunotherapy in breast cancer: Beyond PD-L1 | Bora Lim(MD Anderson Cancer Center, USA) | - |
| 2026-09-03 | 08:30~08:55 | Optimizing perioperative immunotherapy strategies to maximize cure | Hyun Ae Jung(Samsung Medical Center, Korea) | - |
| 2026-09-03 | 08:55~09:20 | Incorporating immunotherapy into curative-intent treatment | Seung-Hoon Beom(Yonsei Cancer Center, Korea) | - |
| 2026-09-03 | 09:20~09:50 | Biomarker-driven strategies for cure in early stage-cancer | Koung Jin Suh(Seoul National University Bundang Hospital, Korea) | - |
| 2026-09-03 | 09:50~10:10 | 휴식 | - | - |
| 2026-09-03 | 10:30~11:10 | New concepts in cancer biology: From the microbiome to non-coding DNA(A룸 강연 동시송출) | Emile E. Voest(Netherlands Cancer Institute and Oncode Institute, Netherlands) | - |
| 2026-09-03 | 11:10~11:20 | 휴식 | - | - |
| 2026-09-03 | 11:20~12:00 | Bridging NATALEE to clinical practice: Updates and insights in HR+/HER2‑ early breast cancer | Kyoung Eun Lee(Ehwa Womans University Mokdong Hospital, Korea) | - |
| 2026-09-03 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-03 | 12:10~12:32 | Recent advances in the management of primary brain tumor | Patrick Wen(Dana Farber Cancer Institute, USA) | - |
| 2026-09-03 | 12:32~12:54 | Integration of systemic therapy and radiation for brain metastases | Yun-Gyoo Lee(Kangbuk Samsung Hospital, Korea) | - |
| 2026-09-03 | 12:54~13:16 | Prophylactic cranial irradiation: Patient selection & real-world evidences | Si Yeol Song(Asan Medical Center, Korea) | - |
| 2026-09-03 | 13:16~13:40 | Radiation toxicities: Radionecrosis and neurocognitive decline | Hidefumi Aoyama(Hokkaido University, Japan) | - |
| 2026-09-03 | 13:40~13:50 | 휴식 | - | - |
| 2026-09-03 | 13:50~14:15 | The next decade of mCRPC therapies: From immune cell engagers to targeted protein degradation and beyond | Joseph Kim(Yale School of Medicine, USA) | - |
| 2026-09-03 | 14:15~14:40 | Advancing biomarker-driven decisions: When and how to use ctDNA in urothelial cancer | Minsuk Kwon(Samsung Medical Center, Korea) | - |
| 2026-09-03 | 14:40~15:10 | Reclaiming cure in relapsed testicular germ cell tumors: Conventional and high dose salvage chemotherapy and treatment approaches for refractory patients | Carsten Bokemeyer(University Medical Center Hamburg-Eppendorf, Hamburg, Germany) | - |
| 2026-09-03 | 15:10~15:30 | 휴식 | - | - |
| 2026-09-03 | 15:30~16:10 | Targeting RAS: What have we learned? What are we learning? What do we need to learn?(A룸 강연 동시송출) | David S. Hong(MD Anderson Cancer Center, USA) | - |
| 2026-09-03 | 16:10~16:32 | Circulating tumor DNA (ctDNA) in peri-operative treatment for hepatocellular carcinoma: Potential and challenges | Hui-Chuan Sun(Liver Cancer Institute and Zhongshan Hospital, China) | - |
| 2026-09-03 | 16:32~16:54 | The role of ctDNA-guided MRD monitoring in pancreatic cancer management | Myung Ah Lee(The Catholic University of Korea Seoul St. Mary’s Hospital, Korea) | - |
| 2026-09-03 | 16:54~17:16 | Integrating ctDNA-based MRD into clinical decision-making in colorectal cancer | Sae-Won Han(Seoul National University Hospital, Korea) | - |
| 2026-09-03 | 17:16~17:40 | Integrating ctDNA-based MRD into surgical decision-making for pancreatic cancer | Sung Hwan Lee(CHA University Bundang Medical Center, Korea) | - |
| 2026-09-03 | 08:30~08:52 | GA-guided treatment decisions to protect quality of life | Hyera Kim(Keimyung University Dongsan Hospital, Korea) | - |
| 2026-09-03 | 08:52~09:14 | Emerging toxicities of novel therapies: Impact on geriatric syndromes | Hee Kyung Ahn(Samsung Medical Center, Korea) | - |
| 2026-09-03 | 09:14~09:36 | Bridging the digital divide in geriatric oncology: Nurse-led digital support | Jiyeon Lee(Yonsei University College of Nursing, Korea) | - |
| 2026-09-03 | 09:36~10:00 | Financial toxicity in older adults: Interventions to improve access and adherence | Shin Hye Yoo(Seoul National University Hospital, Korea) | - |
| 2026-09-03 | 10:00~10:10 | 휴식 | - | - |
| 2026-09-03 | 10:30~11:10 | New concepts in cancer biology: From the microbiome to non-coding DNA(A룸 강연 동시송출) | Emile E. Voest(Netherlands Cancer Institute and Oncode Institute, Netherlands) | - |
| 2026-09-03 | 11:10~11:20 | 휴식 | - | - |
| 2026-09-03 | 11:20~12:00 | Precision beyond standard: Ivosidenib for IDH1m CCA | Changhoon Yoo(Asan Medical Center, Korea) | - |
| 2026-09-03 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-03 | 12:10~12:35 | ctDNA 101 for oncologists: What the assay can and cannot tell you | Beung-Chul Ahn(National Cancer Center, Korea) | - |
| 2026-09-03 | 12:35~13:00 | Metastatic ctDNA profiling: Clinical interpretation masterclass | Gyeong-Won Lee(Gyeongsang National University Hospital, Korea) | - |
| 2026-09-03 | 13:00~13:30 | ctDNA MRD & molecular monitoring: From adjuvant decisions to metastatic dynamics | Young Kwang Chae(Northwestern University, USA) | - |
| 2026-09-03 | 13:30~13:50 | 휴식 | - | - |
| 2026-09-03 | 13:50~14:15 | Targeting tumor-associated antigens: From target biology to therapeutic modalities | Junho Chung(Seoul National University, Korea) | - |
| 2026-09-03 | 14:15~14:40 | Recent advances in antibody–drug conjugates: From novel payloads to clinical impact | Junghoon Shin(Samsung Medical Center, Korea) | - |
| 2026-09-03 | 14:40~15:10 | Recent advances in bispecific T-cell engagers: Engineering immune synapses for cancer therapy | Min Hee Hong(Yonsei Cancer Center, Korea) | - |
| 2026-09-03 | 15:10~15:30 | 휴식 | - | - |
| 2026-09-03 | 15:30~16:10 | Targeting RAS: What have we learned? What are we learning? What do we need to learn?(A룸 강연 동시송출) | David S. Hong(MD Anderson Cancer Center, USA) | - |
| 2026-09-03 | 16:10~16:32 | Peptide receptor radionuclide therapy for neuroendocrine tumors | Gary Ku(Novartis Pharmaceuticals, Singapore) | - |
| 2026-09-03 | 16:32~16:54 | 3D multi-omic mapping of tumors for precision oncology | Denis Wirtz(Johns Hopkins University, USA) | - |
| 2026-09-03 | 16:54~17:16 | Synthetic torpor: Inducing systemic metabolic suppression to starve solid tumors | Jeremy Borniger(Cold Spring Harbor Laboratory, USA) | - |
| 2026-09-03 | 17:16~17:40 | Development of fusion protein-targeted therapies in sarcoma: Opportunities and challenges | Sung Wook Seo(Samsung Medical Center, Korea) | - |
| 2026-09-03 | 08:30~08:52 | Optimizing cancer pain management: Translating recent guidelines into clinical practice | Brian Le(The Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Australia) | - |
| 2026-09-03 | 08:52~09:14 | Modern management of cancer-related dyspnea: From mechanisms to therapeutics | David Hui(MD Anderson Cancer Center, USA) | - |
| 2026-09-03 | 09:14~09:36 | Navigating the complexity of cancer-related delirium: Diagnostic precision and therapeutic innovation | Hyeyoun Park (Seoul National University Bundang Hospital, Korea) | - |
| 2026-09-03 | 09:36~10:00 | Clinical strategies for the imminent death phase: Management of terminal-specific issues | Jung Hun Kang(Gyeongsang National University Hospital, Korea) | - |
| 2026-09-03 | 10:00~10:10 | 휴식 | - | - |
| 2026-09-03 | 10:30~11:10 | New concepts in cancer biology: From the microbiome to non-coding DNA(A룸 강연 동시송출) | Emile E. Voest(Netherlands Cancer Institute and Oncode Institute, Netherlands) | - |
| 2026-09-03 | 11:10~11:20 | 휴식 | - | - |
| 2026-09-03 | 11:20~12:00 | One year since the FLAURA2 OS update: Shaping the new standard in EGFRm+ NSCLC | Taekeun Park(Seoul National University Hospital, Korea) | - |
| 2026-09-03 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-03 | 12:10~12:35 | Why tissue-agnostic strategies matter in rare cancers: Rationale and evidences (From KOSMOS experience) | Soohyeon Lee(Korea University Anam Hospital, Korea) | - |
| 2026-09-03 | 12:35~13:00 | How basket trials are changing rare cancer treatment: Small populations but big targets | Shumei Kato(UCSD, USA) | - |
| 2026-09-03 | 13:00~13:30 | Unlocking immunotherapy in rare cancers: Targeting shared and personal mutations with peptide vaccines | Patrick Ott(Dana-Farber Cancer Institute, USA) | - |
| 2026-09-03 | 13:30~13:50 | 휴식 | - | - |
| 2026-09-03 | 13:50~14:00 | (ORAL) Clinicopathological characteristics of patients with minimal residual disease in stage II–III colon cancer: Interim results from the observational cohort of claudia study | Minsu Kang(Seoul National University Bundang Hospital, Korea) | - |
| 2026-09-03 | 14:00~14:10 | (ORAL) HIPEC plus tislelizumab and SOX for Gastric/GEJ adenocarcinoma with peritoneal metastasis: Interim efficacy and safety of a prospective phase II study | Yigang Zhang(The First Affiliated Hospital with Nanjing Medical University, China) | - |
| 2026-09-03 | 14:10~14:20 | (ORAL) The DEXPARE study: Efficacy of dexamethasone-sparing netupitant-based antiemetic prophylaxis in highly emetogenic chemotherapy | Soorej Balan Kaliyath(All India Institute of Medical Sciences, Mangalagiri, India) | - |
| 2026-09-03 | 14:20~14:30 | (ORAL) Efficacy of neoadjuvant chemotherapy in carcinoma esophagus: A prospective randomized controlled trial comparing cisplatin 5FU versus paclitaxel carboplatin with 5-year survival outcomes | Rohan Kapoor(All India Institute of Medical Sciences, India) | - |
| 2026-09-03 | 14:30~14:40 | (ORAL) Generation specific venous thromboembolism risk associated with EGFR tyrosine kinase inhibitors in non-small cell lung cancer: A nationwide claims-based cohort study | Yun-Gyoo Lee(Kangbuk Samsung Hospital, Korea) | - |
| 2026-09-03 | 14:40~14:50 | (ORAL) An adverse epithelial–endothelial module enriched in high-fss tumors predicts poor outcomes after bladder-preserving chemoradiotherapy | Takuya Tsujino(Osaka Medical and Pharmaceutical University, Japan) | - |
| 2026-09-03 | 15:20~15:30 | 휴식 | - | - |
| 2026-09-03 | 15:30~16:10 | Targeting RAS: What have we learned? What are we learning? What do we need to learn?(A룸 강연 동시송출) | David S. Hong(MD Anderson Cancer Center, USA) | - |
| 2026-09-03 | 16:10~16:32 | Body composition as a treatable trait: Imaging biomarkers for precision oncology | In Gyu Hwang(Chung-Ang University Hospital, Korea) | - |
| 2026-09-03 | 16:32~16:54 | Artificial intelligence in breast imaging: Applications for cancer detection and risk prediction | Manisha Bahl(Massachusetts General Hospital, USA) | - |
| 2026-09-03 | 16:54~17:16 | Imaging biomarkers and radiomics for predicting treatment response in precision oncology | Kyung Won Kim(Asan Medical Center, Korea) | - |
| 2026-09-03 | 17:16~17:40 | Imaging biomarkers for the detection and assessment of metastatic disease in cancer | Young Han Lee(Severance Hospital, Korea) | - |
| 2026-09-03 | 08:30~09:10 | Beyond neoadjuvant therapy: How CheckMate-77T is reshaping the perioperative treatment paradigm in resectable NSCLC | Jang Ho Cho(Gachon University Gil Medical Center, Korea) | - |
| 2026-09-03 | 09:10~09:20 | 휴식 | - | - |
| 2026-09-03 | 09:20~10:00 | Shifting the paradigm: IMDELLTRA in second line treatment | Tae-Hwan Kim(Ajou University Hospital, Korea) | - |
| 2026-09-03 | 10:00~10:10 | 휴식 | - | - |
| 2026-09-03 | 10:30~11:10 | New concepts in cancer biology: From the microbiome to non-coding DNA(A룸 강연 동시송출) | Emile E. Voest(Netherlands Cancer Institute and Oncode Institute, Netherlands) | - |
| 2026-09-03 | 11:10~11:20 | 휴식 | - | - |
| 2026-09-03 | 11:20~12:00 | The sustainable efficacy in HR+, HER2- High risk early breast cancer based on MonarchE 7yrs. data | Heejung Chae(Seoul National University Bundang Hospital, Korea) | - |
| 2026-09-03 | 12:00~12:10 | 휴식 | - | - |
| 2026-09-03 | 12:10~12:50 | Lurbinectedin in SCLC: The earlier, the longer, the better | Sun Min Lim(Severance Hospital, Korea) | - |
| 2026-09-03 | 12:50~13:00 | 휴식 | - | - |
| 2026-09-03 | 13:00~13:40 | Efficiency, and beyond: Driving HER2 care transformation with Phesgo SC | Kabsoo Shin(The Catholic University of Korea Seoul St. Mary’s Hospital, Korea) | - |
| 2026-09-03 | 13:40~13:50 | 휴식 | - | - |
| 2026-09-03 | 13:50~14:30 | Expanding the therapeutic horizon of Pembrolizumab in gastric and esophageal cancer | Ho Jung An(The Catholic University of Korea ST. Vincent) | - |
| 2026-09-03 | 14:30~15:10 | New horizons in nausea and vomiting management | Minsu Kang(Seoul National University Bundang Hospital, Korea) | - |
| 2026-09-03 | 15:10~15:30 | 휴식 | - | - |
| 2026-09-03 | 15:30~16:10 | Targeting RAS: What have we learned? What are we learning? What do we need to learn?(A룸 강연 동시송출) | David S. Hong(MD Anderson Cancer Center, USA) | - |
| 2026-09-03 | 16:10~16:50 | From upfront NGS to targeted therapy in cholangiocarcinoma: Real-world experience with pemigatinib | Jeesun Yoon(Seoul National University Hospital, Korea) | - |
| 2026-09-03 | 16:50~17:00 | 휴식 | - | - |
| 2026-09-03 | 17:00~17:40 | Advancing long-term survival in ALK+ mNSCLC: Value of upfront Lorlatinib based on the CROWN 7y data | Ja Hyun Yeo(Yonsei Cancer Center, Korea) | - |
비고
구분 즉시등록(5월 15일까지) 사전등록(7월 31일까지) 일반등록(8월 1일부터)교수/전문의(학교 및 병원) 회원 150,000원 200,000원 250,000원비회원 170,000원 230,000원 300,000원전임의/간호사/약사/군관 50,000원 60,000원 80,000원업체 및 기타 170,000원 230,000원 300,000원전공의/학생/대학생 무료
문의처
담당자
김예지
연락처
02-735-2857
이메일
meetings@ksmo.or.kr